↑ 薬物リストへ　← 戻る

Tadalafil, placebo    (DrugBank: Tadalafil)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
86肺動脈性肺高血圧症2

86. 肺動脈性肺高血圧症　［臨床試験数：1,083，薬物数：667（DrugBank：122），標的遺伝子数：98，標的パスウェイ数：185］
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,083 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01200732
(ClinicalTrials.gov)		February 20088/9/2010Phosphodiesterase-5 Inhibitor in Eisenmenger SyndromeClinical Efficacy of Phosphodiesterase-5 Inhibitor Tadalafil in Eisenmenger Syndrome - A Randomised, Placebo Controlled, Double Blind, Crossover StudyEisenmenger SyndromeDrug: Tadalafil, placeboGovind Ballabh Pant HospitalNULLCompleted18 YearsN/ABoth28Phase 2India
2JPRN-JapicCTI-132356
22/11/2013A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients with Pulmonary Arterial HypertensionA Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension Hypertension, PulmonaryIntervention name : Tadalafil, Placebo
Dosage And administration of the intervention : Tadalafil doses may range from 5 mg to 40 mg depending on body weight cohorts.		Eli Lilly Japan K.K.NULLrecruitingBOTHPhase 3NULL